720 for a drug that surely should be in a cheaper generic form.
Evekeo is essentially a generic sold as a name brand--any company can sell a mixture of racemic amphetamine, it isn't subject to patents.
And they do. Adderal is 75% d amphetamine 25% l amphetamine. Why anyone would want a higher proportion of l ampehtamine baffles me, as it would basically just increase peripheral stimulation and side effects.
Which is probably why no one else is bothering to sell a 50-50 mixture.
the pharma industry is raping us
The problem here is whatever pharma sales rep convinced your doctor that Evekeo was a good idea.
You say you had too many side effects on vyvanse--vyvanse is 100% d-amphetamine, bonded to lysine (an amino acid) to ensure a slightly more gradual release and eliminate the possibility of non-oral use like snorting (since it has to be processed first to remove the lysine anyway). D-amphetamine generlaly shows less side effects than l-amphetamine, though some people get better results from a bit of a mixture, as in adderral.
Too many side effects with vyvanse, a gradual release 100% d-amphetamine medication, is a problem unlikely to go away by adding some l-amphetmaine into the mix. Most knowledgable doctors would either try reducing the dose and staying with vyvanse, or switching to multiple instant release smaller doses of dextroamphetamine (same active ingredient as vyvanse, 100% d-amphetamine), or switching to a methylphendiate based medication, or trying one of the second-line treatements (buproprion, straterra, etc). Even if deciding to try a mix of l-amphetamine, then there is absolutely no reason not to simply go with the more moderate mixture of adderral.
The likelihood is he doesn't understand the medications well and some pharma rep sold him on this "great new drug." Is this your primary care doc? Try getting a psyciatrist that regularly treats ADHD, at least until you have arrived at a good fit medication and had a proper dose titrated. Primary care docs really aren't qualified to do a good job at that.